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Abstract The G protein-coupled human gastrin-releasing pep-
tide receptor (hGRP-R) is frequently found aberrantly ex-
pressed in human cancers of the colon, stomach, and lung, and
its ligand-speci¢c activation has been implicated in cell prolifer-
ation and di¡erentiation. Here, we demonstrated hGRP-R
activation stimulated sustained cyclic AMP response element
binding protein (CREB) phosphorylation and transactiva-
tion in duodenal cancer cells through a protein kinase C and
partially p38 mitogen-activated protein kinase-dependent path-
way. In contrast, intracellular calcium, ERK1/2, protein kinase
A, and PI3 kinase were not involved. This novel signaling mech-
anism might be of importance for regulation of CREB-depen-
dent gene expression in human cancer expressing functional
hGRP-R. 1 2002 Published by Elsevier Science B.V. on be-
half of the Federation of European Biochemical Societies.
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1. Introduction
The human gastrin-releasing peptide receptor (hGRP-R)
belongs to the mammalian bombesin (Bn) receptors which
comprise a family of three Gq protein-coupled receptors, in-
cluding the GRP-R, the neuromedin B receptor, and the
orphan bombesin receptor subtype 3 [1]. GRP-R mediates
diverse physiological central nervous and gastrointestinal
functions by binding of its speci¢c ligand, the regulatory
GRP [2]. Noticeably, hGRP-R is often found aberrantly ex-
pressed in human cancers of the colon, stomach, lung, breast,
and prostate [1]. When aberrantly expressed in cancer, GRP-
R has been implicated to mediate the e¡ects of GRP primarily
as a potent mitogen and as morphogen, thus having an im-
portant role in human cancer [3^5]. However, the underlying
intracellular signaling mechanisms of this receptor involved in
human carcinogenesis have not been fully elucidated.
In this study, we demonstrated for the ¢rst time that ligand-
speci¢c hGRP-R activation in duodenal cancer cells mediated
sustained cyclic AMP response element binding protein
(CREB) phosphorylation and transactivation in a protein ki-
nase C (PKC)- and partially p38 mitogen-activated protein
kinase (MAPK)-dependent, but protein kinase A (PKA)-,
ERK1/2-, and calcium-independent manner. Since CREB is
a critical transcription factor involved in many cellular func-
tions [6], our results suggest the possibility that this novel
signaling pathway might result in long-term regulation of
CREB-dependent gene transcription relevant in human cancer
cells expressing functional hGRP-R.
2. Materials and methods
2.1. Materials
Forskolin (FSK) and phorbol 12-myristate 13-acetate (PMA) were
purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). Bisindol-
ylmaleimide I (GFX), SB 203580, U 0126, H-89, wortmannin, rapa-
mycin, BAPTA/AM, and thapsigargin were purchased from Calbio-
chem (San Diego, CA, USA). Bn was from Calbiochem (San Diego,
CA, USA). The GRP-R antagonists (3-phenylpropanolyl-D-Ala24,
Pro26, Psi26;27, Phe27)GRP-(20^27) (BW2258U89) and (D-F5-Phe6,
D-Ala11)Bn(6^13)methyl ester (ME) were kindly provided by Drs.
T.W. Moody and R.T. Jensen (National Institutes of Health; Bethes-
da, MD, USA). Antibodies were obtained from Cell Signaling Tech-
nology, Inc. (Beverly, MA, USA).
2.2. Cells
HuTu 80 cells, a duodenal cancer cell line, were obtained from
ATCC and cultured in Dulbecco’s modi¢ed Eagle’s medium, supple-
mented with 10% fetal bovine serum. Prior to Bn stimulation, cells
were synchronized in serum-free medium for 36 h.
2.3. Plasmids and transient transfections
Reporter plasmids pFR-Luc, pFA2-CREB (fusion transactivator)
were purchased from Stratagene (La Jolla, CA, USA). 4USom-
CRE-Luc plasmid (containing four copies of the rat somatostatin
gene CRE sequence in pT81Luc) was generously provided by Prof.
Knepel (University of Go«ttingen, Go«ttingen, Germany). pCMVL-gal
expression vector was purchased from Clontech Laboratories, Inc.
(Palo Alto, CA, USA). For transient transfections, cells were trans-
fected with reporter plasmid and fusion transactivator plasmid using
lipofectAMINE1 reagent (Life Technologies, Inc., Carlsbad, CA,
USA). pCMVL-gal plasmid was co-transfected into cells along with
the reporter plasmid to assess transfection e⁄ciency. Cells were
treated with Bn and FSK for 16 h and harvested for luciferase and
L-galactosidase activity assay as previously described [7].
2.4. Western blot analysis
Cells were lysed in sample bu¡er (62.5 mM Tris^HCl (pH 6.8 at
25‡C), 2% w/v SDS, 10% glycerol, 50 mM dithiothreitol, 0.01% w/v
bromophenol blue). Samples containing equal amounts of total pro-
tein were resolved in 10% SDS^polyacrylamide gel, transferred to
nitrocellulose, incubated with the primary antibody at 4‡C overnight,
and ¢nally incubated with the secondary antibody for 1 h at room
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temperature. The antibody^antigen complexes were then detected us-
ing ECL reagent (Amersham Pharmacia Biotech Inc.; Arlington
Heights, IL, USA).
3. Results
3.1. Bn stimulates sustained CREB phosphorylation at Ser133
via hGRP-R in HuTu 80 cells
The tetradecapeptide Bn is the amphibian homologue of the
27-amino acid mammalian GRP and possesses speci¢c, high-
a⁄nity binding properties on the GRP-R [1]. Using a speci¢c
antibody against the phosphorylated form of CREB at Ser133
in immunoblots, we showed that hGRP-R mediated Bn-de-
pendent CREB phosphorylation in HuTu 80 cells in a dose-
dependent manner (Fig. 1A). Bn-induced CREB phosphory-
lation occurred as early as 5 min after Bn stimulation (data
not shown), and was sustained for at least 8 h (Fig. 1B). Since
the primary structures of the CREB family all contain the
same kinase-inducible domain (KID) region, the anti-phospho
CREB-speci¢c antibody (Ser133) also detected the phosphory-
lated form of ATF-1. Our data showed that ATF-1 phosphor-
ylation was induced concomitantly with Bn-induced CREB
phosphorylation. To determine the speci¢city of Bn-induced
CREB phosphorylation through hGRP-R activation, we used
the speci¢c GRP-R antagonists BW2258U89 and ME 20 min
before stimulation with Bn. Both BW2258U89 and ME abol-
ished Bn-induced CREB phosphorylation as shown in Fig.
1C.
3.2. Bn-induced CREB phosphorylation is PKC-dependent,
but PKA- and calcium-independent
To investigate upstream signaling molecules, we investi-
gated Bn-induced CREB phosphorylation in the presence of
di¡erent inhibitors. Pretreatment of cells with the PKC inhib-
itor GFX (2 WM) completely abolished CREB phosphoryla-
tion (Fig. 2A). In contrast, GFX did not a¡ect FSK-induced
CREB phosphorylation (data not shown). Furthermore, after
down-regulation of PKC by long-term pretreatment with
PMA (100 nM; 40 h) Bn induced CREB phosphorylation
only marginally (Fig. 2B). In contrast, treatment with PMA
alone for 30 min resulted in enhanced CREB phosphoryla-
tion, and Bn stimulation following short-term PMA treatment
further induced CREB phosphorylation (Fig. 2B). The PKA
inhibitor H-89 (20 WM) did not a¡ect Bn-stimulated CREB
phosphorylation (Fig. 2C), whereas it almost abolished FSK-
Fig. 1. CREB is phosphorylated at Ser133 via hGRP-R activation in
HuTu 80 cells. A: CREB phosphorylation (P-CREB) after Bn stim-
ulation for 30 min occurred in a dose-dependent manner. B: Bn
(10 nM) induced sustained CREB phosphorylation for at least 8 h
(con1 is Bn at 0 min, con2 is vehicle control at 8 h). C: Pretreat-
ment with hGRP-R antagonists BW2258U89 (1 WM) and ME (100
nM) for 20 min prior to stimulation with Bn (10 nM) for 30 min
abolished Bn-induced CREB phosphorylation. ME+Bn (1) and
ME+Bn (2) are independent duplicates of the same treatment (Bn
stimulation after ME pretreatment). Both, phosphorylated CREB at
Ser133 (P-CREB) and total CREB, were detected by immunoblot-
ting. Anti-phospho-CREB-speci¢c antibody also detected the phos-
phorylated form of the CREB-related ATF-1 (P-ATF-1).
Fig. 2. Bn-induced CREB phosphorylation is PKC- but not PKA-
dependent. A: Pretreatment with GFX (2 WM) prior to Bn (10 nM)
stimulation abolished CREB phosphorylation completely at 15 and
30 min, respectively. B: Down-regulation of PKC with long-term
PMA pretreatment (100 nM; 40 h) diminished the Bn-dependent
CREB phosphorylation. Short-term incubation (30 min) with PMA
alone enhanced CREB phosphorylation. C: Pretreatment with H-89
(20 WM) abolished FSK (25 WM)-induced CREB phosphorylation
but had no e¡ect on CREB phosphorylation in response to Bn
stimulation for 15 and 30 min, respectively.
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induced CREB phosphorylation as expected. To determine
whether calcium-dependent pathways are involved, BAPTA/
AM (30 WM) was used to chelate intracellular Ca2þ, and
thapsigargin (2 WM) was used to inhibit intracellular Ca2þ
release before Bn stimulation. We found that inhibition of
intracellular calcium elevation did not yield any changes of
Bn-induced CREB phosphorylation (data not shown). Simi-
larly, inhibition of PI3 kinase signaling with wortmannin (200
nM) or inhibition of p70 S6 kinase with rapamycin (100 nM)
did not a¡ect Bn-induced CREB phosphorylation (data not
shown).
3.3. p38 MAPK pathway might be involved in Bn-induced
CREB phosphorylation
To further explore alternative signal mechanisms involved
in Bn-dependent CREB phosphorylation, we investigated the
activation of di¡erent MAPK pathways. Using a phospho-
speci¢c p38 MAPK antibody, we showed that Bn stimulated
p38 MAPK phosphorylation moderately in a sustained man-
ner (Fig. 3A). p38 MAPK phosphorylation occurred from
10 min to at least 4 h after Bn stimulation. Using the p38
MAPK inhibitor SB 203580 (20 WM) prior to Bn stimulation,
we demonstrated that Bn-induced CREB phosphorylation
was partially reduced, but not abolished (Fig. 3B), suggesting
that the p38 MAPK pathway might be partially responsible
for CREB phosphorylation. Furthermore, we showed that
this inhibitor at 20 WM reduced p38 MAPK phosphorylation
activated by Bn concomitantly with inhibition of CREB
phosphorylation (Fig. 3B,C). In additional experiments, we
showed that Bn did not induce p44/42 MAPK phosphoryl-
Fig. 3. p38 MAPK pathway might be partially involved in CREB
phosphorylation via hGRP-R activation. A: Bn (10 nM) induced
moderate sustained p38 MAPK phosphorylation for at least 4 h.
B: Pretreatment with SB 203580 (20 WM) before Bn stimulation re-
sulted in reduction of CREB phosphorylation. C: p38 MAPK phos-
phorylation was abolished by SB 203580 (20 WM). p38 MAPK dual
phosphorylation at Thr180 and Tyr182 was detected by immunoblot
using a phospho-speci¢c anti-p38 MAPK antibody (P-p38MAPK).
Fig. 4. E¡ects of Bn-dependent hGRP-R activation on CREB tran-
scriptional activity and CRE-directed gene transcription. CREB
transcriptional activation was assessed using a trans-reporter system
in HuTu 80 cells. A: Cells were treated with vehicle, Bn (1 and 10
nM), and FSK (25 WM) for 16 h before cell lysis. Relative luciferase
activity is expressed as mean value compared to activity measured
in vehicle controls. Values are expressed as the mean (S S.E.M.) of
¢ve independent experiments, each performed in triplicate. B: Ef-
fects of GFX (2 WM) and SB 203580 (20 WM) on Bn (10 nM)- and
FSK (25 WM)-induced CREB transactivation were expressed as the
percentage of relative luciferase activity compared to control. Values
are expressed as the mean (S S.E.M.) of four independent experi-
ments, each performed in triplicate. C: The 4USomCRE-Luc plas-
mid was transiently transfected into HuTu 80 cells to assess the ef-
fect of hGRP-R activation on CRE-directed gene transcription.
Cells were treated with Bn and FSK (25 WM) for 16 h before cell
lysis as indicated. Relative luciferase activity is expressed as mean
value in each experiment compared to controls. Values are ex-
pressed as the mean (S S.E.M.) of ¢ve independent experiments,
each performed in triplicate.
FEBS 26420 28-8-02
X. Qu et al./FEBS Letters 527 (2002) 109^113 111
ation, and the MEK inhibitor U0216 (20 WM) did not a¡ect
Bn-induced CREB phosphorylation (data not shown). More-
over, inhibition of PKC by GFX (2 WM) did not reduce p38
MAPK phosphorylation (data not shown).
3.4. Human GRP-R activation mediates transcriptional activity
of CREB as determined by a GAL4^CREB fusion protein
To examine whether hGRP-R activation can stimulate
CREB-dependent transcriptional activity, we co-transfected
a pFA2-CREB expression plasmid and a pFR-Luc reporter
plasmid into HuTu 80 cells. The pFA2-CREB plasmid con-
tains the human cytomegalovirus immediate early promoter to
drive the constitutive expression of a fusion protein consisting
of the activation domain of CREB fused with the yeast GAL4
DNA binding domain. Cells were treated with Bn and FSK
for 16 h prior to cell harvest. Our results showed that both
FSK and Bn resulted in increased CREB transactivation as
measured by luciferase gene reporter assay in HuTu 80 cells
(Fig. 4A). To further explore the role of PKC and the p38
MAPK pathway in Bn-induced CREB transactivation, we in-
cubated the cells with GFX and SB 203580, respectively, prior
to stimulation with Bn and FSK. GFX reduced Bn-induced
CREB transactivation by almost 80% and SB 203580 dimin-
ished it by approximately 60%. In contrast, neither GFX nor
SB 203580 resulted in any changes of FSK-induced CREB
transactivation (Fig. 4B). These data provided further evi-
dence that PKC as well as p38 MAPK activation are likely
involved in Bn-dependent CREB phosphorylation and trans-
activation.
3.5. CRE-directed gene transcription is induced via hGRP-R
activation
To determine whether Bn-induced CREB phosphorylation
induced CRE-directed gene transcription, we tested a CRE
reporter plasmid [8] in transient co-transfection experiments.
Cells were transfected with a 4USomCRE-Luc reporter plas-
mid along with the pCMVL-gal plasmid. Stimulation with Bn
for 16 h before cell harvest increased transcription of the lu-
ciferase reporter gene in a dose-dependent manner (Fig. 4C),
suggesting that Bn-induced CREB phosphorylation and trans-
activation can enhance CRE-directed gene transcription in
HuTu 80 cells.
4. Discussion
CREB, a 43 kDa leucine zipper transcription factor, is a
main regulator of gene expression which mediates the activa-
tion of cAMP-responsive genes by binding as a dimer to a
conserved cAMP-responsive element (CRE), characterized by
the nucleotide octamer sequence TGACGTCA [6,9]. It was
among the ¢rst transcription factors, which were shown to
be regulated by phosphorylation. The transactivation domain
of CREB consists of constitutive and an inducible domain
that synergize in response to cAMP stimulation [10]. The
KID is activated only when phosphorylated at Ser133 [11].
Phosphorylation at this site potentiates activity of the KID
by promoting recruitment of the co-activator paralogues CBP
and p300 to the target promoter [12].
We showed that CREB phosphorylation at Ser133 occurred
in response to FSK, a stimulus known to produce CREB
phosphorylation via a cAMP-dependent pathway, in duode-
nal cancer cells. In contrast, our studies are the ¢rst to dem-
onstrate that Bn induced robust CREB phosphorylation sus-
tained for at least 8 h. This e¡ect is distinct from FSK-
induced phosphorylation, which typically elicits a rapid,
short-lived response. Our ¢ndings are speci¢c for ligand-in-
duced hGRP-R activation because Bn-induced CREB phos-
phorylation occurred even at sub-nanomolar concentrations,
and speci¢c receptor antagonists abolished the e¡ect.
CREB is a substrate for many kinases other than PKA,
including PKC, AKT, calcium-calmodulin-dependent kinases,
mitogen/stress-activated kinase, and pp90rsk [6]. In this study,
we determined further upstream signaling molecules involved
in Bn-induced CREB phosphorylation. Bn has previously
been shown to regulate transcription factor AP-1 activation
through a PKC-dependent pathway in human gastric cancer
SIIA cells [13]. However, it was not reported whether regula-
tory peptides induced PKC activation and subsequent CREB
phosphorylation, which in turn could direct CRE-directed
gene transcription. Our current study showed that Bn induced
CREB phosphorylation, and its transcriptional activation is
PKC- and partially p38 MAPK-dependent. Using immuno-
blot experiments, we demonstrated Bn-induced CREB phos-
phorylation was abolished in the presence of a PKC inhibitor,
but not a PKA inhibitor. Furthermore, Bn also resulted in
transcriptional CREB activation using a GAL4^CREB lucif-
erase reporter system. Corresponding to our immunoblot
data, pretreatment with GFX reduced Bn-induced CREB
transcriptional activity, whereas it had no e¡ect on FSK-in-
duced CREB transcriptional activity.
In most circumstances, Bn was shown to raise cytosolic
calcium levels, i.e. in pancreatic L cells Bn-induced insulin
secretion was shown to be dependent on the increase of intra-
cellular calcium [14]. However, in HuTu 80 cells, depletion of
intracellular calcium by thapsigargin and BAPTA/AM did not
prevent Bn-induced CREB phosphorylation, suggesting that
Bn-induced CREB phosphorylation is calcium-independent.
Insulin-like growth factor I and nerve growth factor were
shown to elicit p38 MAPK activation and result in CREB
phosphorylation in PC12 cells, a pheochromocytoma cell
line [15,16]. In rat pancreatic acini, Bn as well as cholecysto-
kinin stimulated p38 MAPK activation [17]. Bn-induced AP-1
activation also required p38 MAPK activation in an intestinal
epithelial cell line transfected with the murine GRP-R [18].
We show in this study that Bn induced sustained p38
MAPK phosphorylation for at least 4 h. Furthermore, our
observations that SB 203580 reduced Bn-induced CREB phos-
phorylation and transactivation in immunoblot experiments
and GAL4^CREB reporter system assays, respectively, sug-
gest the possibility that p38 MAPK is partially responsible for
Bn-induced CREB phosphorylation in HuTu 80 cells. SB
203580, a pyridinylimidazole compound, was initially found
to be a selective inhibitor of p38 MAPK by competitive bind-
ing in the ATP pocket of p38 MAPK [19]. Although it is
widely used as a speci¢c inhibitor of p38 MAPK, it is also
capable of inhibiting other protein kinases, such as p56 lck,
c-src, and JNK2 L1 [20,21]. Therefore, our study cannot ex-
clude the possibility that kinases other than p38 MAPK are
involved in Bn-dependent CREB phosphorylation. We also
found that inhibition of PKC by GFX did not abolish p38
MAPK phosphorylation, suggesting that Bn-induced CREB
phosphorylation might be mediated by two independent path-
ways.
CREB-mediated transcription regulates diverse cellular
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events including cellular metabolic regulation, cell survival
and apoptosis, neuronal signaling and immune system func-
tion [6]. Previously, Bn was shown to activate CRE-mediated
transcription in HIT-T15 cells, a hamster pancreatic L cell line
[22]. However, the cellular events leading to Bn-induced CRE-
mediated transcription were not further investigated. We dem-
onstrate here that Bn had the ability to activate CRE-depen-
dent transcription in gastrointestinal cancer cells with endo-
genously expressed, functional hGRP-R. Furthermore, our
data indicate that Bn-induced CREB phosphorylation and
transactivation might be responsible for transcription directed
by the rat somatostatin CRE site. However, it still needs to be
explored in future studies whether Bn-dependent CREB phos-
phorylation and regulation of downstream gene expression
are similar or distinct compared with cAMP-dependent path-
ways. In this study, we used a human cancer cell line which
possesses the native, functional GRP-R, and its ligand-speci¢c
activation was previously shown not to induce cell prolifera-
tion [23]. Therefore, one might speculate that hGRP-R-medi-
ated CREB phosphorylation could be involved in gastrointes-
tinal carcinogenesis through molecular mechanisms other than
promoting cell proliferation directly. In this respect, it will be
of considerable interest to further identify possible CREB-
dependent target genes regulated through activation of
hGRP-R.
Acknowledgements: This work was supported by a Foundation for
Digestive Health and Nutrition (FDHN)/Research Scholar Award
and the NIH (DK02722) (to H.C.W.).
References
[1] Kroog, G.S., Jensen, R.T. and Battey, J.F. (1995) Med. Res.
Rev. 15, 389^417.
[2] Sunday, M.E., Kaplan, L.M., Motoyama, E., Chin, W.W. and
Spindel, E.R. (1988) Lab. Invest. 59, 5^24.
[3] Carroll, R.E., Matkowskyj, K.A., Tretiakova, M.S., Battey, J.F.
and Benya, R.V. (2000) Cell Growth Di¡er. 11, 385^393.
[4] Markwalder, R. and Reubi, J.C. (1999) Cancer Res. 59, 1152^
1159.
[5] Jensen, J.A., Carroll, R.E. and Benya, R.V. (2001) Peptides 22,
689^699.
[6] Mayr, B. and Montminy, M. (2001) Nat. Rev. Mol. Cell Biol. 2,
599^609.
[7] Xiao, D., Wang, J., Hampton, L.L. and Weber, H.C. (2001)
Gene 264, 95^103.
[8] Oetjen, E., Diedrich, T., Eggers, A., Eckert, B. and Knepel, W.
(1994) J. Biol. Chem. 269, 27036^27044.
[9] Comb, M., Birnberg, N.C., Seasholtz, A., Herbert, E. and Good-
man, H.M. (1986) Nature 323, 353^356.
[10] Brindle, P., Linke, S. and Montminy, M. (1993) Nature 364, 821^
824.
[11] Arias, J., Alberts, A.S., Brindle, P., Claret, F.X., Smeal, T., Ka-
rin, M., Feramisco, J. and Montminy, M. (1994) Nature 370,
226^229.
[12] Kwok, R.P. et al. (1994) Nature 370, 223^226.
[13] Kim, H.J., Evers, B.M., Litvak, D.A., Hellmich, M.R. and
Townsend Jr., C.M. (2000) Am. J. Physiol. Cell Physiol. 279,
C326^C334.
[14] Wollheim, C.B. and Pralong, W.F. (1990) Biochem. Soc. Trans.
18, 111^114.
[15] Xing, J., Kornhauser, J.M., Xia, Z., Thiele, E.A. and Greenberg,
M.E. (1998) Mol. Cell Biol. 18, 1946^1955.
[16] Pugazhenthi, S., Miller, E., Sable, C., Young, P., Heidenreich,
K.A., Boxer, L.M. and Reusch, J.E. (1999) J. Biol. Chem. 274,
27529^27535.
[17] Schafer, C., Ross, S.E., Bragado, M.J., Groblewski, G.E., Ernst,
S.A. and Williams, J.A. (1998) J. Biol. Chem. 273, 24173^24180.
[18] Guo, Y.S., Hellmich, M.R., Wen, X.D. and Townsend Jr., C.M.
(2001) J. Biol. Chem. 276, 22941^22947.
[19] LoGrasso, P.V., Frantz, B., Rolando, A.M., O’Keefe, S.J.,
Hermes, J.D. and O’Neill, E.A. (1997) Biochemistry 36, 10422^
10427.
[20] Wadsworth, S.A. et al. (1999) J. Pharmacol. Exp. Ther. 291, 680^
687.
[21] Lee, J.C., Kumar, S., Griswold, D.E., Underwood, D.C., Votta,
B.J. and Adams, J.L. (2000) Immunopharmacology 47, 185^
201.
[22] Eckert, B., Schwaninger, M. and Knepel, W. (1996) Endocrinol-
ogy 137, 225^233.
[23] Williams, B.Y. and Schonbrunn, A. (1994) Cancer Res. 54, 818^
824.
FEBS 26420 28-8-02
X. Qu et al./FEBS Letters 527 (2002) 109^113 113
